Osteoboost Direct Investment Page
BoneHealth Technologies is revolutionizing bone health with Osteoboost. In January 2024, Osteoboost received FDA clearance through the de novo pathway, becoming the first and only FDA-cleared non-pharmacological prescription treatment for low bone density. Results from the clinical trial were used to support FDA clearance for the treatment of osteopenia in postmenopausal women.
SPV Legal Name: Portfolia 2024 SPV 4 LLC (Bone Health SPV) | EIN: 33-2984942
Portfolio Company | In the News
Bone Health Technologies Acquires Wellen Taking a Pivotal Step Toward a Comprehensive One-Stop Bone Health Care for Patients Everywhere
July 25, 2024
Bone Health Technologies Has Launched Pre-Orders for Osteoboost, the First FDA-cleared, Non-Drug Wearable Treatment Designed To Improve Bone Health
December 10, 2024
Performance Overview
Quarterly Reports
The highlights of Q4 2024 updates as provided by the company. Please note all updates provided are confidential and not for distribution. To access the file, use password: Q424BHSPV!
Videos
Company Update and Direct Investment overview from BoneHealth and Portfolia.
Leadership Team
